Skip to main content
. 2019 Nov 14;45(5):546–554. doi: 10.1016/j.jgr.2019.11.005

Table 3.

Mean outcomes at week 0 and week 12 and changes in safety outcomes for all participants in ITT approach (n = 80), by treatment group


Control
Ginseng
Ginseng vs. control p
Safety measures Week 0 Week 12 Change from baseline p Week 0 Week 12 Change from baseline p
Creatinine (mmol/L) 74.08 ± 2.3 71.46 ± 2.3 –2.62 ± 3.2 0.41 74.63 ± 2.4 72.63 ± 2.5 –2.00 ± 3.5 0.56 –1.17 ± 1.6 0.47
Alanine aminotransferase (U/L) 28.61 ± 2.2 26.54 ± 2.3 –2.07 ± 3.2 0.51 31.24 ± 2.7 27.64 ± 2.7 –3.60 ± 3.9 0.35 0.46 ± 2.2 0.92
QT Interval (s) 400.47 ± 4.2 406.66 ± 4.3 6.19 ± 6.0 0.31 387.24 ± 4.2 398.31 ± 4.2 11.07 ± 5.9 0.06 0.62 ± 5.5 0.89
International normalized ratio 1.04 ± 0.01 1.04 ± 0.01 -–0.00 ± 0.01 0.84 1.04 ± 0.01 1.04 ± 0.01 0.00 ± 0.01 1.00 0.00 ± 0.02 0.94
Prothrombin time (s) 2.81 ± 0.05 2.82 ± 0.05 0.01 ± 0.1 0.84 1.82 ± 0.03 1.79 ± 0.03 –0.02 ± 0.04 0.61 0.05 ± 0.5 0.91

All values are mean ± SE. Abbreviations: QT interval-start of Q wave to end of T wave on the 12-lead electrocardiogram; Missing data were obtained by five-fold averaged Multiple Imputations. The p-values for change from baseline determined using Least Squares Means in PROC MIXED. The p-values in the last column indicate the comparison between control and ginseng at 12 weeks corrected for center and baseline by ITT analysis using PROC MIXED.